Emory Winship awards three new endowed chairs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Xingming Deng
David Yu
Hyunsuk Shim

Three members of Winship Cancer Institute’s Department of Radiation Oncology received endowed chair appointments:

  • Xingming Deng is the inaugural holder of the Chair in Cancer Biology.

  • David Yu is the inaugural holder of the Jerome Landry Chair of Cancer Research.

  • Hyunsuk Shim is the inaugural holder of the Crocker Family Chair in Cancer Innovation.

Deng, professor in the Department of Radiation Oncology and director of the discovery theme in Winship’s Discovery and Development Therapeutics Research Program, joined Winship in 2009. He has unique experience in uncovering cell death and DNA repair mechanisms.

He has contributed the understanding of the Bcl-2 and Bax family of proteins and how their anti and pro-apoptotic functions influence the development of aerodigestive malignancies and their subsequent response to anticancer therapies. He has obtained four patents for new anticancer drug discovery.

Yu, associate professor and director of cancer biology in the Department of Radiation Oncology, began his faculty career at Winship in 2010. His research focuses on the role of acetylation in directing the replication stress response and whether it will translate to cancer therapeutics and diagnostics, especially for patients with pancreatic cancer. In 2014, Yu received the Michael Fry Research Award from the Radiation Research Society recognizing the most outstanding junior scientist in the field of radiation research.

Shim, professor and scientific director of medical physics in the Department of Radiation Oncology, is a molecular oncologist with a specialty in diagnostic imaging and drug discovery. In her 16 years at Emory and Winship, she has contributed groundbreaking insights into the involvement of chemokine receptor modulation in cancer invasion and metastasis. She is known as a global expert in working with the alpha chemokine receptor CXCR4. Shim leads Emory’s NCI Quantitative Imaging Network team on developing advanced 3D whole-brain spectroscopic MRI for the management of brain tumor patients.

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login